Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.43 |
| ▸ | DRD2 | P14416 | 6/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561572 | 0.84 | HTR6 (0.46) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL3556346 | 0.82 | HTR6 (0.67) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL3558261 | 0.81 | HTR6 (0.47) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL27544502 | 0.79 | HTR6 (0.65) | HTR6DRD2HTR2AHTR7HTR1A | |
| Hydrochloric Acid SCHEMBL27563048 | 0.78 | HTR6 (0.64) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL3562087 | 0.76 | HTR6 (0.40) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL4525417 | 0.74 | HTR6 (0.41) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL5071407 | 0.72 | HTR6 (0.47) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL5485454 | 0.72 | HTR6 (0.49) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL4813026 | 0.71 | HTR6 (0.67) | HTR6DRD2HTR2AHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1956004-B1 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LTD (GB) | 2012-06-13 | — | — | EP | claimed |
| US-7799774-B2 | Quinoline derivatives and their use as 5-HT6 ligands | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | claimed |
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | claimed |
| EP-1956004-A1 | Quinoline derivatives and their use as 5-HT6 ligands | Glaxo Group Limited (GB) | 2008-08-13 | — | — | EP | claimed |
| US-20050124628-A1 | Novel compounds | ROIVANT NEUROSCIENCES LTD. (BM) | 2005-06-09 | — | — | US | claimed |
| EP-1497266-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | claimed |
| WO-2003080580-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298841-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR3B, HTR4 | HTR6 1/4885DRD2 29/4885HTR2A 9/4885 |
| US-20050124628-A1 | Novel compounds | NLN, ATP6V1B2, CHRNA2 | HTR6 111/4885DRD2 125/4885HTR2A 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.